


**Table S2. Quality assessment of included studies.**

First author	Q1	Q2	Q3	Q4	Q5	Q6	Q7	End Point of 8
Adhiratha	1	1	0	1	1	0	1	5
Alali2008	1	1	1	2	1	1	1	8
AlexandraMoura	1	1	1	2	1	0	1	7
Ali Kazemnia	0	1	0	1	1	1	1	5
Azucena Mora	1	1	1	1	0	1	1	6
Baoguang	1	1	1	1	1	0	1	6
Bhoomika	0	1	1	0	1	0	1	4
Bogaard2001	1	1	1	1	1	0	1	6
Hanna E. Sidjabat	0	1	1	1	1	0	1	5
Iuliana E. Maciuca	0	1	1	1	1	1	1	6
James	1	1	1	2	1	1	1	8
Jing Wang	1	1	1	1	0	1	1	6
Joanne L. Platell	0	1	1	0	0	0	1	3
Jorge Hernandez	0	1	0	1	1	1	1	5
Karen Alroy	0	0	1	0	1	0	1	3
Katherine A. Stenske	1	1	1	2	1	1	1	8
Krushna Chandra	1	1	1	1	1	0	1	6
L. Wang	1	1	1	1	0	1	1	6
Manju Raj Purohit	1	1	1	1	1	1	1	7
Mark R. Sannes	1	1	1	2	1	1	1	8
Miles2006	1	1	1	1	0	1	1	6
Miles2006	1	1	1	1	0	1	1	6
Montserrat Sabate	1	1	1	1	1	0	1	6
Pankaj Dhaka	1	1	1	1	0	1	1	6
Adhiratha**	1	1	0	1	1	0	1	5
Adhiratha Boonyasiri	1	1	0	1	1	0	1	5
TATSUYA	1	1	1	1	0	0	1	5
Pasquali2015*	1	1	1	1	0	0	1	5
ROSS	0	1	1	1	0	1	1	5

Ryszard Koczura	1	1	1	2	1	1	1	8
Sayah2005	1	1	0	1	1	0	1	5
SCOTT	1	1	1	2	0	1	1	7
Thomas*	1	0	0	1	0	0	1	3
Thorsteinsdottir	0	1	1	1	0	1	1	5
VIKTORIA*	0	1	1	1	0	0	1	4
WINOKUR	0	1	1	1	1	0	1	5
Yolanda***	0	1	1	0	1	0	1	4
Young	0	1	1	1	1	1	1	6



<b>Model</b>	<b>Effect size and 95% interval</b>				<b>Test of null (2-Tail)</b>		<b>Heterogeneity</b>			
<b>Model</b>	<b>Number Studies</b>	<b>Point estimate</b>	<b>Lower limit</b>	<b>Upper limit</b>	<b>Z-value</b>	<b>P-value</b>	<b>Q-value</b>	<b>df (Q)</b>	<b>P-value</b>	<b>I-squared</b>
Fixed	4	0.461	0.427	0.496	-2.208	0.027	297.505	3	0.000	98.992
Random	4	0.219	0.052	0.586	-1.538	0.124				

Fig S1. Prevalence of clinical (human) MDR *E.coli* isolates with Disk Diffusion method.




Fig S2. Prevalence of clinical (human) ESBL *E.coli* isolates with Disk Diffusion method




Fig S3. Prevalence of Colistin resistance *E.coli* clinical (human) isolates with Disk Diffusion method.




Fig S4. Prevalence of Ciprofloxacin resistance *E.coli* clinical (human) isolates with Disk Diffusion method.




Fig S5. Prevalence of trimethoprim resistance *E.coli* clinical (human) isolates with Disk Diffusion method.




Fig S6. Prevalence of Sulfoxazole resistance E.coli clinical (human) isolates with Disk Diffusion method.






Fig S7. Prevalence of Ofloxacin resistance E.coli clinical (human) isolates with Disk Diffusion method.




Fig S8. Prevalence of Cephalothin resistance E.coli clinical (human) isolates with Disk Diffusion method.




Fig S9. Prevalence of Amikacin resistance E.coli clinical (human) isolates with Disk Diffusion method.




Fig S10. Prevalence of Amoxicillin/clavulanic acid resistance E.coli clinical (human) isolates with Disk Diffusion method.




Fig S511. Prevalence of amoxicillin resistance E.coli clinical (human) isolates with Disk Diffusion method.




Fig S12. Prevalence of Cefoxitin resistance E.coli clinical (human) isolates with Disk Diffusion method.




Fig S13. Prevalence of Cefotaxim resistance E.coli clinical (human) isolates with Disk Diffusion method.




Fig S14. Prevalence of Chloramphenicol resistance E.coli clinical (human) isolates with Disk Diffusion method.






Fig S15. Prevalence of Ceftriaxone resistance E.coli clinical (human) isolates with Disk Diffusion method.




Fig S16. Prevalence of Imipenem resistance E.coli clinical (human) isolates with Disk Diffusion method.




Fig S17. Prevalence of Trimethoprim/sulfamethoxazole resistance E.coli clinical (human) isolates with Disk Diffusion method.




Fig S18. Prevalence of Tetracycline resistance E.coli clinical (human) isolates with Disk Diffusion method.




Fig S19. Prevalence of Gentamicin resistance E.coli clinical (human) isolates with Disk Diffusion method.




Fig S20. Prevalence of kanamycin resistance E.coli clinical (human) isolates with Disk Diffusion method.




Fig S21. Prevalence of Nalidixic acid resistance E.coli clinical (human) isolates with Disk Diffusion method.




Fig S22. Prevalence of Ampicillin resistance E.coli clinical (human) isolates with Disk Diffusion method.






Fig S23. Prevalence of Ceftazidim resistance E.coli clinical (human) isolates with Disk Diffusion method.




Fig S24. Prevalence of Aztreonam resistance E.coli clinical (human) isolates with Disk Diffusion method.




Fig S25. Prevalence of streptomycin resistance *E.coli* clinical (human) isolates with Disk Diffusion method.




Fig S26. Prevalence of MDR *E.coli* animal isolates with Disk Diffusion method.




Fig S27. Prevalence of ESBL *E.coli* animal isolates with Disk Diffusion method.




Fig S28. Prevalence of Colistin resistance animal isolated *E.coli* with Disk Diffusion method.




Fig S29. Prevalence of Ciprofloxacin resistance animal isolated *E.coli* with Disk Diffusion method.




Fig S30. Prevalence of Trimethoprim resistance animal isolated *E.coli* with Disk Diffusion method.






Fig S31. Prevalence of Sulfisoxazole resistance animal isolated *E.coli* with Disk Diffusion method.





Fig S32. Prevalence of Cephalothin resistance animal isolated *E.coli* with Disk Diffusion method.



Model	Effect size and 95% interval				Test of null (2-Tail)		Heterogeneity			
	Number Studies	Point estimate	Lower limit	Upper limit	Z-value	P-value	Q-value	df (Q)	P-value	I-squared
Fixed	3	0.033	0.017	0.064	-9.636	0.000	6.783	2	0.034	70.513
Random	3	0.018	0.003	0.108	-4.159	0.000				

Fig S33. Prevalence of Amikacin resistance animal isolated *E.coli* with Disk Diffusion method.




Fig S34. Prevalence of Amoxicillin/ Clavulanic acid resistance animal isolated *E.coli* with Disk Diffusion method.




Fig S35. Prevalence of Cefoxitin resistance animal isolated *E.coli* with Disk Diffusion method.




Fig S36. Prevalence of Cefotaxim resistance animal isolated *E.coli* with Disk Diffusion method.




Fig S37. Prevalence of Chloramphenicol resistance animal isolated *E.coli* with Disk Diffusion method.




Fig S38. Prevalence of Ceftriaxone resistance animal isolated *E.coli* with Disk Diffusion method.




Fig S39. Prevalence of Imipenem resistance animal isolated *E.coli* with Disk Diffusion method.






Fig S40. Prevalence of Trimethoprim/sulfamethoxazole resistance animal isolated *E.coli* with Disk Diffusion method.




Fig S41. Prevalence of Tetracycline resistance animal isolated *E.coli* with Disk Diffusion method.




Fig S42. Prevalence of Gentamicin resistance animal isolated *E.coli* with Disk Diffusion method.




Fig S43. Prevalence of Nalidixic acid resistance animal isolated *E.coli* with Disk Diffusion method.




Fig S44. Prevalence of Ampicillin resistance animal isolated *E.coli* with Disk Diffusion method.




Fig S45. Prevalence of Ceftazidim resistance animal isolated *E.coli* with Disk Diffusion method.




Fig S46. Prevalence of Streptomycin resistance animal isolated *E.coli* with Disk Diffusion method.




Fig S47. Prevalence of Colistin resistance environment/food isolated *E.coli* with Disk Diffusion method.







Fig S48. Prevalence of Ciprofloxacin resistance environment/food isolated *E.coli* with Disk Diffusion method.



Model	Effect size and 95% interval				Test of null (2-Tail)		Heterogeneity			
	Number Studies	Point estimate	Lower limit	Upper limit	Z-value	P-value	Q-value	df (Q)	P-value	I-squared
Fixed	2	0.179	0.136	0.231	-9.300	0.000	26.973	1	0.000	96.293
Random	2	0.213	0.046	0.603	-1.487	0.137				

Fig S49. Prevalence of Sulfoxazole resistance environment/food isolated *E.coli* with Disk Diffusion method.





Fig S50. Prevalence of Cephalothin resistance environment/food isolated *E.coli* with Disk Diffusion method.



Model	Effect size and 95% interval				Test of null (2-Tail)		Heterogeneity			
	Number Studies	Point estimate	Lower limit	Upper limit	Z-value	P-value	Q-value	df (Q)	P-value	I-squared
Fixed	3	0.054	0.029	0.096	-8.968	0.000	6.046	2	0.049	66.919
Random	3	0.041	0.012	0.134	-4.837	0.000				

Fig S51. Prevalence of Amikacin resistance environment/food isolated *E.coli* with Disk Diffusion method.




Fig S52. Prevalence of Amoxicillin/Clavulanic acid resistance environment/food isolated *E.coli* with Disk Diffusion method.




Fig S53. Prevalence of Cefoxitin resistance environment/food isolated *E.coli* with Disk Diffusion method.




Fig S54. Prevalence of Cefotaxim resistance environment/food isolated *E.coli* with Disk Diffusion method.





Fig S55. Prevalence of Chloramphenicol resistance environment/food isolated *E.coli* with Disk Diffusion method.





Model	Effect size and 95% interval				Test of null (2-Tail)		Heterogeneity			
Model	Number Studies	Point estimate	Lower limit	Upper limit	Z-value	P-value	Q-value	df (Q)	P-value	I-squared
Fixed	2	0.016	0.002	0.107	-4.065	0.000	0.432	1	0.511	0.000
Random	2	0.016	0.002	0.107	-4.065	0.000				

Fig S56. Prevalence of Ceftriaxone resistance environment/food isolated *E.coli* with Disk Diffusion method.





Fig S57. Prevalence of Imipenem resistance environment/food isolated *E.coli* with Disk Diffusion method.



Model	Effect size and 95% interval				Test of null (2-Tail)		Heterogeneity			
	Number Studies	Point estimate	Lower limit	Upper limit	Z-value	P-value	Q-value	df (Q)	P-value	I-squared
Fixed	7	0.182	0.142	0.230	-9.965	0.000	120.683	6	0.000	95.028
Random	7	0.258	0.081	0.577	-1.515	0.130				

Fig S58. Prevalence of Trimethoprim/sulfamethoxazole resistance environment/food isolated *E.coli* with Disk Diffusion method.




Fig S59. Prevalence of Tetracycline resistance environment/food isolated *E.coli* with Disk Diffusion method.





Fig S60. Prevalence of Gentamicin resistance environment/food isolated *E.coli* with Disk Diffusion method.



Model	Effect size and 95% interval				Test of null (2-Tail)		Heterogeneity			
	Number Studies	Point estimate	Lower limit	Upper limit	Z-value	P-value	Q-value	df (Q)	P-value	I-squared
Fixed	2	0.647	0.580	0.708	4.202	0.000	41.539	1	0.000	97.593
Random	2	0.304	0.014	0.929	-0.477	0.633				

Fig S61. Prevalence of Kanamycin resistance environment/food isolated *E.coli* with Disk Diffusion method.





Fig S62. Prevalence of Nalidixic acid resistance environment/food isolated *E.coli* with Disk Diffusion method.



Model	Effect size and 95% interval				Test of null (2-Tail)		Heterogeneity			
	Number Studies	Point estimate	Lower limit	Upper limit	Z-value	P-value	Q-value	df (Q)	P-value	I-squared
Fixed	8	0.466	0.419	0.514	-1.374	0.169	246.187	7	0.000	97.157
Random	8	0.402	0.165	0.695	-0.639	0.523				

Fig S63. Prevalence of Ampicillinresistance environment/food isolated *E.coli* with Disk Diffusion method.






Fig S64. Prevalence of Ceftazidim resistance environment/food isolated *E.coli* with Disk Diffusion method.




Fig S65. Prevalence of Streptomycin resistance environment/food isolated *E.coli* with Disk Diffusion method.




Fig S66. Prevalence of human, animal and environment/food isolated MDR *E.coli* with MIC method.






Fig S67. Prevalence of human, animal and environment/food isolated ESBL *E.coli* with MIC method.




Groups		Effect size and 95% interval			Test of null (2-Tail)		Heterogeneity			
Group	Number Studies	Point estimate	Lower limit	Upper limit	Z-value	P-value	Q-value	df (Q)	P-value	I-squared
<b>Fixed effect analysis</b>										
Animal	1	0.001	0.000	0.020	-4.725	0.000	0.000	0	1.000	0.000
Human	3	0.078	0.059	0.104	-15.766	0.000	3.607	2	0.165	44.552
Total within							3.607	2	0.165	
Total between							8.791	1	0.003	
Overall	4	0.075	0.056	0.099	-16.190	0.000	12.398	3	0.006	75.802

Fig S68. Prevalence of human, animal and environment/food Ciprofloxacin resistance *E. coli* isolation with MIC method.



Groups	Effect size and 95% interval				Test of null (2-Tail)		Heterogeneity			
Group	Number Studies	Point estimate	Lower limit	Upper limit	Z-value	P-value	Q-value	df (Q)	P-value	I-squared
<b>Mixed effects analysis</b>										
Animal	15	0.075	0.037	0.144	-6.710	0.000	684.950	14	0.000	97.956
Food/Env	4	0.057	0.010	0.268	-3.058	0.002	45.848	3	0.000	93.457
Human	18	0.077	0.037	0.154	-6.265	0.000	1249.401	17	0.000	98.639
Total between							1980.199	34	0.000	
Overall	37	0.074	0.046	0.118	-9.671	0.000	72.038	2	0.000	
							2052.237	36	0.000	98.246

Fig S69. Prevalence of human, animal and environment/food Ciprofloxacin resistance *E.coli* isolation with MIC method.



Groups	Effect size and 95% interval				Test of null (2-Tail)		Heterogeneity			
Group	Number Studies	Point estimate	Lower limit	Upper limit	Z-value	P-value	Q-value	df (Q)	P-value	I-squared
<b>Mixed effects analysis</b>										
Animal	6	0.309	0.178	0.480	-2.177	0.029	149.495	5	0.000	96.655
Food/Env	1	0.237	0.161	0.333	-4.802	0.000	0.000	0	1.000	0.000
Human	8	0.222	0.100	0.423	-2.610	0.009	146.587	7	0.000	95.225
Total between							296.082	12	0.000	
Overall	15	0.252	0.189	0.327	-5.812	0.000	3.040	2	0.219	
							299.122	14	0.000	95.320

Fig S70. Prevalence of human, animal and environment/food trimethoprim resistance *E. coli* isolation with MIC method.




Fig S71. Prevalence of human, animal and environment/food Sulfisoxazole resistance *E.coli* isolation with MIC method.






Fig S72. Prevalence of human, animal and environment/food Cephalothin resistance *E.coli* isolation with MIC method.





Fig S73. Prevalence of human, animal and environment/food Amikacin resistance *E.coli* isolation with MIC method.



Groups	Effect size and 95% interval				Test of null (2-Tail)		Heterogeneity				
	Group	Number Studies	Point estimate	Lower limit	Upper limit	Z-value	P-value	Q-value	df (Q)	P-value	I-squared
<b>Mixed effects analysis</b>											
Animal	5	0.030	0.019	0.046	-15.099	0.000	8.218	4	0.084	51.324	
Food/Env	1	0.128	0.058	0.256	-4.397	0.000	0.000	0	1.000	0.000	
Human	6	0.045	0.020	0.099	-7.099	0.000	188.888	5	0.000	97.353	
Total between							197.105	9	0.000		
Overall	12	0.042	0.030	0.059	-16.963	0.000	111.437	2	0.000		
							308.542	11	0.000	96.435	

Fig S74. Prevalence of human, animal and environment/food Amoxicillin/Clavulanic acid resistance *E.coli* isolation with MIC method.




Fig S75. Prevalence of human, animal and environment/food Amoxicillin resistance *E.coli* isolation with MIC method.




Fig S76. Prevalence of human, animal and environment/food Cefotaxim resistance *E.coli* isolation with MIC method.




Fig S77. Prevalence of human, animal and environment/food Chloramphenicol resistance *E.coli* isolation with MIC method.




Fig S78. Prevalence of human, animal and environment/food Ceftriaxone resistance *E.coli* isolation with MIC method.




Fig S79. Prevalence of human, animal and environment/food Imipenem resistance *E.coli* isolation with MIC method.








Fig S80. Prevalence of human, animal and environment/food Trimethoprim/sulfamethoxazole resistance *E.coli* isolation with MIC method.




Groups	Effect size and 95% interval				Test of null (2-Tail)		Heterogeneity				
	Group	Number Studies	Point estimate	Lower limit	Upper limit	Z-value	P-value	Q-value	df (Q)	P-value	I-squared
<b>Mixed effects analysis</b>											
Animal	16	0.600	0.459	0.725	1.394	0.163	1341.805	15	0.000	98.882	
Food/Env	3	0.410	0.041	0.920	-0.255	0.799	161.317	2	0.000	98.760	
Human	15	0.373	0.270	0.488	-2.150	0.032	390.660	14	0.000	96.416	
Total between							1893.783	31	0.000		
Overall	34	0.464	0.376	0.554	-0.780	0.435	2371.389	2	0.000		
							4265.172	33	0.000	99.226	

Fig S81. Prevalence of human, animal and environment/food Tetracycline resistance *E.coli* isolation with MIC method.



Groups	Effect size and 95% interval				Test of null (2-Tail)		Heterogeneity			
Group	Number Studies	Point estimate	Lower limit	Upper limit	Z-value	P-value	Q-value	df (Q)	P-value	I-squared
<b>Mixed effects analysis</b>										
Animal	11	0.095	0.036	0.229	-4.248	0.000	1486.079	10	0.000	99.327
Food/Env	3	0.106	0.020	0.404	-2.398	0.016	37.921	2	0.000	94.726
Human	12	0.051	0.020	0.122	-6.002	0.000	417.502	11	0.000	97.365
Total between							1941.501	23	0.000	
Overall	26	0.072	0.039	0.130	-7.661	0.000	763.220	2	0.000	
							2704.721	25	0.000	99.076

Fig S82. Prevalence of human, animal and environment/food Gentamicin resistance *E.coli* isolation with MIC method.



Groups	Effect size and 95% interval				Test of null (2-Tail)		Heterogeneity			
	Number Studies	Point estimate	Lower limit	Upper limit	Z-value	P-value	Q-value	df (Q)	P-value	I-squared
<b>Mixed effects analysis</b>										
Animal	10	0.152	0.073	0.290	-4.080	0.000	1022.457	9	0.000	99.120
Food/Env	3	0.170	0.041	0.499	-1.965	0.049	45.706	2	0.000	95.624
Human	10	0.062	0.020	0.174	-4.596	0.000	377.033	9	0.000	97.613
Total between							1445.197	20	0.000	
Overall	23	0.121	0.069	0.203	-6.282	0.000	261.830	2	0.000	
							1707.027	22	0.000	98.711

Fig S83. Prevalence of human, animal and environment/food Kanamycin resistance *E.coli* isolation with MIC method.





Fig S84. Prevalence of human, animal and environment/food Nalidixic acid resistance *E.coli* isolation with MIC method.



Groups	Effect size and 95% interval				Test of null (2-Tail)		Heterogeneity			
Group	Number Studies	Point estimate	Lower limit	Upper limit	Z-value	P-value	Q-value	df (Q)	P-value	I-squared
<b>Mixed effects analysis</b>										
Animal	11	0.310	0.171	0.495	-2.015	0.044	1128.362	10	0.000	99.114
Food/Env	3	0.294	0.051	0.763	-0.840	0.401	103.661	2	0.000	98.071
Human	12	0.334	0.184	0.527	-1.698	0.089	1720.487	11	0.000	99.361
Total between							2952.510	23	0.000	
Overall	26	0.320	0.215	0.446	-2.756	0.006	106.372	2	0.000	
							3058.882	25	0.000	99.183

Fig S85. Prevalence of human, animal and environment/food Ampicillinresistance *E.coli* isolation with MIC method.





Fig S86. Prevalence of human, animal and environment/food Ceftazidim resistance *E.coli* isolation with MIC method.




Groups	Effect size and 95% interval				Test of null (2-Tail)		Heterogeneity			
Group	Number Studies	Point estimate	Lower limit	Upper limit	Z-value	P-value	Q-value	df (Q)	P-value	I-squared
<b>Mixed effects analysis</b>										
Animal	10	0.367	0.241	0.514	-1.779	0.075	447.055	9	0.000	97.987
Food/Env	1	0.039	0.020	0.073	-9.441	0.000	0.000	0	1.000	0.000
Human	11	0.277	0.141	0.473	-2.210	0.027	461.515	10	0.000	97.833
Total between							908.570	19	0.000	
Overall	22	0.172	0.123	0.235	-7.798	0.000	398.031	2	0.000	
							1306.601	21	0.000	98.393

Fig S87. Prevalence of human, animal and environment/food Streptomycin resistance *E.coli* isolation with MIC method.



Group by published time	Study name	Statistics for each study					Events/Total	Event rate and 95% CI
		Event rate	Lower limit	Upper limit	Z-Value	p-Value		
2001.00	Yolanda	0.008	0.002	0.031	-6.790	0.000	2 / 250	
2001.00	Yolanda*	0.096	0.061	0.149	-8.789	0.000	17 / 177	
2001.00	Yolanda**	0.128	0.058	0.256	-4.397	0.000	6 / 47	
2001.00	Yolanda***	0.160	0.148	0.173	-34.722	0.000	521 / 3260	
2001.00	Bogaard2001	0.004	0.000	0.062	-3.882	0.000	0 / 122	
2001.00	Bogaard2001*	0.049	0.022	0.104	-7.096	0.000	6 / 123	
2001.00	Bogaard2001**	0.005	0.000	0.079	-3.689	0.000	0 / 93	
2001.00	WINCKUR	0.333	0.084	0.732	-0.800	0.423	2 / 6	
2001.00	WINCKUR*	0.153	0.081	0.268	-4.736	0.000	9 / 59	
2001.00		0.077	0.043	0.134	-7.863	0.000	563 / 4137	
2005.00	Young	0.328	0.267	0.396	-4.765	0.000	66 / 201	
2005.00	Young*	0.012	0.003	0.047	-6.203	0.000	2 / 167	
2005.00	Young**	0.314	0.264	0.369	-6.234	0.000	93 / 296	
2005.00	Thomas	0.002	0.000	0.033	-4.338	0.000	0 / 232	
2005.00	Thomas*	0.013	0.004	0.039	-7.460	0.000	3 / 232	
2005.00	SCOTT	0.002	0.000	0.015	-6.148	0.000	1 / 472	
2005.00	SCOTT*	0.001	0.000	0.021	-4.681	0.000	0 / 376	
2005.00		0.027	0.009	0.081	-6.081	0.000	165 / 1976	
2008.00	Alali2008	0.008	0.006	0.011	-26.754	0.000	31 / 3891	
2008.00	Alali2008*	0.000	0.000	0.002	-8.138	0.000	1 / 3428	
2008.00	Thorsteinsdottir	0.040	0.013	0.117	-5.393	0.000	3 / 75	
2008.00	Thorsteinsdottir*	0.189	0.151	0.234	-10.578	0.000	65 / 344	
2008.00		0.014	0.001	0.130	-3.527	0.000	100 / 7738	
2009.00	VIKTORIA	0.034	0.005	0.208	-3.274	0.001	1 / 29	
2009.00	VIKTORIA*	0.024	0.001	0.287	-2.594	0.009	0 / 20	
2009.00		0.030	0.006	0.138	-4.172	0.000	1 / 49	
2010.00	Tatsuya	0.072	0.039	0.129	-7.790	0.000	10 / 139	
2010.00	Tatsuya*	0.072	0.054	0.094	-16.897	0.000	47 / 654	
2010.00	Tao Lei	0.309	0.245	0.381	-4.962	0.000	55 / 178	
2010.00	Tao Lei*	0.636	0.603	0.668	7.846	0.000	542 / 852	
2010.00		0.209	0.046	0.591	-1.534	0.125	654 / 1823	
2011.00	TATSUYA	0.125	0.007	0.734	-1.287	0.198	0 / 3	
2011.00	TATSUYA*	0.417	0.185	0.692	-0.575	0.566	5 / 12	
2011.00	TATSUYA**	0.111	0.047	0.241	-4.384	0.000	5 / 45	
2011.00		0.204	0.062	0.498	-1.973	0.049	10 / 60	
2014.00	Adhiratha	0.607	0.575	0.638	6.395	0.000	550 / 906	
2014.00	Adhiratha*	0.102	0.046	0.208	-5.058	0.000	6 / 59	
2014.00		0.302	0.032	0.849	-0.641	0.522	556 / 965	
2015.00	Pasquali2015	0.098	0.037	0.233	-4.227	0.000	4 / 41	
2015.00	Pasquali2015*	0.217	0.176	0.266	-9.481	0.000	70 / 322	
2015.00		0.166	0.076	0.325	-3.579	0.000	74 / 363	
2016.00	ROSS	0.008	0.000	0.110	-3.434	0.001	0 / 65	
2016.00	ROSS*	0.007	0.000	0.099	-3.517	0.000	0 / 73	
2016.00		0.007	0.001	0.049	-4.915	0.000	0 / 138	
2018.00	Baoguang	0.390	0.325	0.459	-3.085	0.002	78 / 200	
2018.00	Baoguang*	0.268	0.226	0.313	-8.918	0.000	107 / 400	
2018.00		0.324	0.217	0.454	-2.625	0.009	185 / 600	
Overall		0.134	0.101	0.175	-11.476	0.000	2308 / 17849	



Groups		Effect size and 95% interval			Test of null (2-Tail)		Heterogeneity		
Group	Number Studies	Point estimate	Lower limit	Upper limit	Z-value	P-value	Q-value	df (Q)	P-value
<b>Mixed effects analysis</b>									
2001.000	9	0.077	0.043	0.134	-7.863	0.000	48.640	8	
2005.000	7	0.027	0.009	0.081	-6.081	0.000	118.107	6	
2008.000	4	0.014	0.001	0.130	-3.527	0.000	250.007	3	
2009.000	2	0.030	0.006	0.138	-4.172	0.000	0.047	1	
2010.000	4	0.209	0.046	0.591	-1.534	0.125	421.601	3	
2011.000	3	0.204	0.062	0.498	-1.973	0.049	5.478	2	
2014.000	2	0.302	0.032	0.849	-0.641	0.522	35.919	1	
2015.000	2	0.166	0.076	0.325	-3.579	0.000	3.016	1	
2016.000	2	0.007	0.001	0.049	-4.915	0.000	0.003	1	
2018.000	2	0.324	0.217	0.454	-2.625	0.009	9.286	1	
Total between							892.105	27	
Overall	37	0.134	0.101	0.175	-11.476	0.000	1160.132	9	
							2052.237	36	

Fig S88. Global prevalence of Ciprofloxacin resistance isolates from 2000 to 2018.




Fig S89 . Global prevalence of Amoxicillin resistance E. coli clinical (human) isolates in WHO regional offices with MIC method.




Fig S90 . Global prevalence of Tetracycline resistance E. coli clinical (human) isolates in WHO regional offices with MIC method.